# US 2026/0097078 A1 · Regulation of cells and organisms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097078 A1
- Document ID: US20260097078A1
- Status: Published application
- Kind: A1
- Application number: 19/335,476
- Filed: 2025-09-22
- Published: 2026-04-09
- Earliest claimed: 2021-04-05
- Inventors: Victor TETS; Georgy TETS
- Web page: https://patentgrep.com/patent/US20260097078A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/19: Platelets; Megacaryocytes
- A61P 35/00: Antineoplastic agents
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to medicine, biology, veterinary, pharmacology diagnostics, agriculture, ecology, meteorology, seismology, construction biotechnology, biomanufacturing and provided herein are products and methods for managing cells behavior, memory of cells and erasure of cell memory. The present invention describes products and methods that, unlike the known ones, make it possible to control the properties of cells and organisms without the use of mutagens and/or the special introduction of genes and/or use of specific gene tools and/or changing its environmental conditions.

## Claims

### Claim 1

A cell that is treated with one or more of an RNase, a DNase, enzyme with nuclease activity an antibody that binds to an RNA and an antibody that binds to a DNA.

### Claim 2 (depends on 1)

The cell of claim 1, wherein the cell is a eukaryotic or prokaryotic.

### Claim 3 (depends on 1)

The cell of claim 1, wherein the treatment comprises treating the cell with an RNase or with an antibody that binds to an antibody that binds to an RNA only.

### Claim 4 (depends on 1)

The cell of claim 1, wherein the treatment comprises treating the cell with a DNase or with an antibody that binds to an antibody that binds to an DNA only.

### Claim 5 (depends on 1)

The cell of claim 1, wherein the treatment comprises treating the cell with an antibody that binds to an antibody that binds to an RNA only.

### Claim 6 (depends on 1)

The cell of claim 1, wherein the treatment comprises treating the cell with an antibody that binds to an antibody that binds to a DNA only.

### Claim 7 (depends on 1)

The cell of claim 1, wherein the cell is the part of organoid, organ, multicellular organism

### Claim 8 (depends on 1)

The cell of claim 1, wherein the treatment comprises treating the cell two or more times with one or more of an RNase, a DNase, an antibody that binds to an RNA and an antibody that binds to a DNA.

### Claim 9 (depends on 1)

The cell of claim 1, wherein the cell is treated first with an RNase and then with a DNase.

### Claim 10 (depends on 1)

The cell of claim 1, wherein the cell is treated first with a DNase and then with an RNase.

### Claim 11 (depends on 1)

The cell of claim 1, wherein the cell is treated first with a DNase and then with an antibody that binds to a DNA.

### Claim 12 (depends on 1)

The cell of claim 1, wherein the cell is treated first with an RNase and then with an antibody that binds to an RNA.

### Claim 13 (depends on 1)

The cell of claim 1, wherein the cell is treated first with a DNase and then with an antibody to an RNA.

### Claim 14 (depends on 1)

The cell of claim 1, wherein the cell is treated first with an RNase and then with an antibody to a DNA.

### Claim 15 (depends on 1)

The cell of claim 1, wherein the cell is treated with three of an RNase, a DNase, an antibody that binds an RNA and an antibody that binds to a DNA.

### Claim 16 (depends on 1)

The cell of claim 1, wherein the cell is treated with all four of an RNase, a DNase, an antibody that binds an RNA and an antibody that binds to a DNA.

### Claim 17 (depends on 1)

The cell of claim 1, wherein the treated cell is a white blood cell.

### Claim 18 (depends on 16)

The cell of claim 16, wherein the cell is a B cell, a T cell, a macrophage, a neutrophil, an NK cell or a dendritic cell.

### Claim 19 (depends on 1)

The cell of claim 1, wherein following the treatment, the cell produces a bioproduct.

### Claim 20 (depends on 18)

The cell of claim 18, wherein the bioproduct that is a DNase, an RNase, an anti-DNA antibody and/or an anti-RNA antibody include an antibody, an antibiotic, a cytokine a growth factor, a viral vector, an antigen, a viral vector, a vaccine, complex bivalent biotherapeutic, a trivalent biotherapeutics, a trivalent T-cell engager, a checkpoint modulator, a naive proteins, a recombinant protein, a peptide, a vitamin, a hormone, a vaccine, and an antibody cytokine fusion biomolecule, a clotting and/or a coagulation factor, a TNF inhibitor, an Interferon, a monoclonal antibody, a receptor or a hormone.

### Claim 21 (depends on 18)

The cell of claim 18, wherein the bioproduct is a plant, a grain, a wheat, a fruit, a tomato, a peach, an orange, an apricot, a grape, a hybrid fruit, an apple, a nut, a pecan, a walnut, an almond, a pistachio, a peanut, a coffee bean, a tea, a soybean, a corn, a pea, a carrot, broccoli, squash, cauliflower, a mushroom, a bean, a legume, a barley, a sorgum, a legume or other plant food source.

### Claim 22 (depends on 1)

The products of claim 1, wherein the product is produced by treated cells.
